BC Environmental and Occupational Health Research Network

To meet the objectives outlined in the updated NIAID Strategic Plan for Biodefense Research, it is imperative that promising findings/technologies are translated rapidly into new approaches and strategies for product development. The involvement of experts from diverse disciplines (e.g., biochemists, structural biologists, protein chemists, pharmacologists, immunologists, molecular biologists, engineers and clinicians) within academia and industry is needed to enable development of well-designed candidates for vaccines, vaccine technologies. adjuvants, therapeutics, immunotherapeutics, and medical diagnostics. The objective of this RFA is to support research that will advance the development and/or production of countermeasures (vaccines, adjuvants, therapeutics, immunotherapeutics, and medical diagnostics) specific for NIAID Category A, B, or C priority pathogens or toxins. Developmental research is not required to result in a "final" product but must advance the development of a candidate product. A second objective of this RFA is to stimulate scientifically sound, original, and innovative research requiring a comprehensive team and multidisciplinary effort that will facilitate advancement of a promising candidate product or platform technology through the product development pathway.